Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:59 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose
NCT04715230 · InterveXion Therapeutics, LLC · PHASE2 · terminated · last registry update 2023-11-18 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor decision based on slower than anticipated enrollment leading to fund exhaustion.” | – | Registry record, InterveXion Therapeutics, LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against GABRA1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2024-10-26Results posted on the registry: University of New Mexico, Ketamine + Methohexital (NCT04022226)
- 2024-09-25Also stopped (withdrawn): Henry Ford Health System, Acamprosate + Placebo (NCT06312800)
- 2024-09-19Results posted on the registry: National Cancer Institute (NCI), Cediranib + Sunitinib (NCT01391962)
- 2023-11-13Results posted on the registry: Wake Forest University Health Sciences, Propofol + Methohexital (NCT04187196)
- 2023-08-01Also stopped (withdrawn): University of New Mexico, Acamprosate (Campral) + Acamprosate (NCT00655967)
- 2023-03-09Results posted on the registry: Northwell Health, Ketamine + Methohexital (NCT01881763)
- 2022-12-20Results posted on the registry: Mayo Clinic, Acomprosate (NCT04287920)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision